Winton Group’s Neurogene NGNE Stock Holding History

Winton Group’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,010	Closed	-$242K	–	1450
2020 Q3	$242K	Buy	1,010 +337	+50%	+$81.6K	0.01%	1310
2020 Q2	$223K	Buy	+673	New	+$175K	0.01%	1338

Other funds holding NGNE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Winton Group's NGNE Position: Q4 2020 in Review

Winton Group sold out of Neurogene (NGNE) in Q4 2020, closing a stake of 1,010 shares — an estimated $242K sold.

Winton Group first reported a position in NGNE in Q2 2020 and held it in 2 quarters. The position peaked at $242K in Q3 2020. 84 funds tracked by Wall St. Rank hold NGNE as of Q4 2020.

Winton Group reported no remaining Neurogene position as of Q4 2020 after selling out during the quarter.
Winton Group sold 1,010 Neurogene shares in Q4 2020, an estimated $242K.
Winton Group first reported a position in Neurogene in Q2 2020 and held it in 2 quarters.
Winton Group's Neurogene position peaked at $242K in Q3 2020.
84 funds tracked by Wall St. Rank held Neurogene as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.